0
0

United States Pharmaceutical Supply Chain Review Act

10/15/2024, 11:53 PM

Summary of Bill S 5206

The United States Pharmaceutical Supply Chain Review Act, introduced in the 118th Congress as S.5206 on September 25, 2024, aims to address issues within the pharmaceutical supply chain. It includes provisions focused on reviewing and potentially restructuring aspects of the supply chain to ensure efficiency and accountability. The bill likely mandates assessments of current practices, identifies areas for improvement, and may propose specific changes or regulations to enhance the transparency and effectiveness of pharmaceutical distribution. For detailed information, the official PDF version of the bill can be accessed at https://www.congress.gov/118/bills/s5206/BILLS-118s5206is.pdf.

Current Status of Bill S 5206

Bill S 5206 is currently in the status of Bill Introduced since September 25, 2024. Bill S 5206 was introduced during Congress 118 and was introduced to the Senate on September 25, 2024.  Bill S 5206's most recent activity was Read twice and referred to the Committee on Banking, Housing, and Urban Affairs. as of September 25, 2024

Bipartisan Support of Bill S 5206

Total Number of Sponsors
1
Democrat Sponsors
1
Republican Sponsors
0
Unaffiliated Sponsors
0
Total Number of Cosponsors
1
Democrat Cosponsors
0
Republican Cosponsors
1
Unaffiliated Cosponsors
0

Policy Area and Potential Impact of Bill S 5206

Primary Policy Focus

Alternate Title(s) of Bill S 5206

United States Pharmaceutical Supply Chain Review Act
United States Pharmaceutical Supply Chain Review Act
A bill to require a report on foreign investment in the pharmaceutical industry of the United States.

Comments

Skyler Brewer profile image

Skyler Brewer

685

1 year ago

I'm so excited about this new bill! It's gonna help make sure our meds are safe and affordable. Did you know it also includes provisions to increase transparency in the pharmaceutical supply chain? #knowledgeispower